WO1999065914A1 - Derives de l'artemisinine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent - Google Patents
Derives de l'artemisinine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent Download PDFInfo
- Publication number
- WO1999065914A1 WO1999065914A1 PCT/FR1999/001359 FR9901359W WO9965914A1 WO 1999065914 A1 WO1999065914 A1 WO 1999065914A1 FR 9901359 W FR9901359 W FR 9901359W WO 9965914 A1 WO9965914 A1 WO 9965914A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- compounds
- substituted
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/20—Spiro-condensed systems
Definitions
- the present invention relates to new artemisinin derivatives, their preparation process and the pharmaceutical compositions containing them.
- Artemisinin is an active ingredient isolated from Artemisia annual. L., well known for its activity against malaria.
- the compounds of the present invention are new, and have particularly advantageous pharmacological properties as anti-tumor agents
- R represents the radical of formula (II)
- A represents
- CN a group of formula (III) -CR (m) R in which - R 1 represents an aryl, substituted aryl, heteroaryl or substituted heteroaryl group,
- R 2 represents a hydrogen atom, or a linear or branched alkyl group (Ci -Ce) substituted or not,
- - Y represents a linear or branched alkylene (C 2 -C ⁇ ) group substituted or not, alkenylene (C 2 -C ⁇ 4 ) linear or branched substituted or not, alkynvlene (C 2 -C ⁇ ) linear or branched substituted or not, phenylene, substituted phenvlene, naphthylene, or substituted naphthylene, - Z represents an oxygen or sulfur atom, or a group NR ' 2 or R' 2 can take the same values as R 2 ,
- aryl means a phenyle, naphthyl, phenanthryl, fluorenyl or anthryl group, - by heteroaryl, we mean any mono or bicyc group that aromatic containing from 5 to
- 10 atoms and may contain from 1 to 3 heteroatoms chosen from oxygen, nitrogen or sulfur,
- aryl "," heteroaryl “,” phenylene “,” naphthylene “ means that these groups are substituted by one or more radicals, identical or different, chosen from linear or branched (CC 6 ) alkyl , hydroxy, linear or branched alkoxy (C r C 6 ), alkoxycarbonyl (d-C ⁇ ), linear or branched polyhalogenoalkyl (C ⁇ -C 6 ), aryloxy (not substituted or substituted by one or more groups, identical or different, chosen from hydroxy, alkyl (C ⁇ -C6) linear or branched alkoxy (C ⁇ -C6) linear or branched, polyhaloalkyl (C ⁇ -C6) linear or branched, or halogen atoms), nitro, amino, alkylamino (-C Ce) linear or branched, dialkylamino (C ⁇ -C 6 ) linear or branched, alkylcarbonylamino c
- substitute affecting the expressions "alkyl”, “alkylene”, “alkenylene”, “alkynylene” means that these groups are substituted by one or more radicals, identical or different, chosen from hydroxy, alkoxy (C ⁇ -C 6 ) linear or branched, polyhalogenoalkyle, amino or halogen atoms (fluorine, chlorine, bromine or iodine), their enantiomers and diastereoisomers, as well as their addition salts with a pharmaceutically acceptable acid or base
- hydrochloric bromide, sulphonic, phosphonic, acetic, trifluoroacetic, lactic, pyruvic, succinic malonic, glutinic, fumaic, tartic, maleic, citric, ascorbic, oxalic, methane sulfonic acids. , camphoric, etc
- the preferred compounds of the invention are those for which - A represents a group of formula (III),
- Z represents a group NR ' 2 ,
- - Y represents an alkylene or alkenylene chain (C 2 -Cj), substituted or not, - Y represents a phenvlene or a naphthylene, substituted or not,
- the invention relates to the compounds of formula (I) for which A represents a group of formula (III) or R 1 represents a substituted or unsubstituted phenyl group and R 2 represents a hydrogen atom or a methyl group, or a group of formula (IV) or Y represents a chain - (CH 2 ) n - or n is such that 2 ⁇ n ⁇ 7, Z represents an oxygen atom or a group NR ' 2 and R 3 represents a group of formula (III) where R 1 represents a substituted or unsubstituted phenyl or naphthyl group and R 2 represents a hydrogen atom or a methyl group
- the invention also extends to the process for preparing the compounds of formula (I) characterized in that the compound of formula (V) is used as starting material:
- R and Y are defined as above, on which it is reacted under acid catalysis conditions, in the presence of a coupling agent, or after transformation into the corresponding acid chloride,
- the compound of formula (V) is easily accessible to those skilled in the art by conventional reduction of artemisinin (commercial).
- the compounds of formula (VI) are obtained by conventional condensation of a cyanide salt on the ketone of formula (XI):
- R 1 and R 2 are defined as above.
- the compounds of formula (X) are obtained by the action of H 2 S in the presence of a catalyst such as Al O 3 for example on the compound of formula (VI).
- Another advantageous process of the invention relates to the preparation of the compounds of formula (I) for which A represents a group of formula (IV), characterized in that a compound of formula (VII) is used as starting material :
- R, Y, R 1 . R 2 and R ' 2 are as defined above,
- the compounds of formula (I) have interesting pharmacological properties They have excellent cytotoxicity m vitro not only on leukemic lines but also on solid tumor lines, and also have an action on the cell cycle These properties allow their use in therapeutic as anti-tumor agents
- the present invention also relates to pharmaceutical compositions containing the products of formula (I) their optical isomers or one of their addition salts with a base or a pharmaceutically acceptable acid, alone or in combination with one or more inert non-toxic excipients or vehicles
- compositions according to the invention particular mention will be made of those which are suitable for oral, parenteral, nasal, rectal, perhnal, ocular or respiratory administration and in particular simple or coated tablets, sublingual tablets, sachets, packets , capsules, glossettes, tablets, suppositories creams, ointments, dermal gels, injectable or drinkable preparations, aerosols, eye or nasal drops
- the useful dosage varies according to the age and weight of the patient, the route of administration, the nature of the therapeutic indication and any associated treatments and ranges from 0.1 to
- Examples 4 to 16 are obtained according to the same process from the appropriate nitriles.
- the title product is conventionally obtained by condensation of succinic acid or its anhydride on dihydroartemisinin.
- Stage B 1, 4-Succinate of [(2-kromophenyl) (cyano) methyl] and of dihydroartemisininyl
- Examples 18 to 27 are obtained according to the same process by replacing in stage B 2- (2-bromophenyl) -2-hydroxyacetonitrile with the appropriate reagent.
- EXAMPLE 34 4- (E) -2-Butenedioate of [(2-chlorophenyl) (cyano) methyl] and of dihydroartemisininyl
- EXAMPLE 35 1, 4- (2.3-Dichloro) succinate of
- EXAMPLE 40 4 - ( ⁇ [Cyano] [(3-methoxy-4-benzyloxy) phenyl] methyl ⁇ amino) -4- dihydroartemisininyl oxobutanoate
- Examples 45 to 48 are obtained by proceeding as in Example 1, replacing 2- (4-bromophenyl) -2-hydroxy acetonitrile with the appropriate nitrile.
- Examples 49 to 56 are obtained by proceeding as in Example 42, replacing: - in stage .A benzaldehyde with the appropriate reagent, - in stage B. succinic anhydride with the appropriate reagent.
- Stage A 4-Bromobenzaldehyde
- Stage B Succinic anhydride
- EXAMPLE 50 4 - ⁇ [(Cyano [phenyl] methyl) (methyl) amino] carbonyl ⁇ dihydroartemisininyl benzoate
- Stage A Benzaldehyde
- Stage B 2-Butenedioic acid
- Stage A 2- Bromobenzaldehyde
- Stage B Succinic anhydride
- Examples 57 to 67 are obtained by proceeding as in Example 16, replacing in Step B 2- (2-bromophenyl) -2-hydroxyacetonitrile with the appropriate acetonitrile.
- the cells are cultured in complete RPMI 1640 culture medium containing 10% of fetal calf serum 2 mM of glutam e, 50 units / ml of penicillin, 50 ⁇ g / ml of streptomycin and 10 mM of Hepes
- the cells are distributed in microplates and exposed to cytotoxic compounds. They are then incubated for the time necessary for cell doubling. The number of viable cells is then quantified by a colo ⁇ met ⁇ que test, the Minoculture Tetrazo um Assay (Carmichael J De Graff WG, Gazdar AF , Mmna JD and Mitchell JR, Evaluation of a tetrazo um-based semi-automated colo ⁇ met ⁇ c assay assessment of chemosensitivity testing, Cancer Res, 47 936-942, 1987)
- the L1210 cells are incubated for 21 hours at 37 ° C. in the presence of different concentrations of test products.
- the cells are then fixed with 70% ethanol (V / V), washed twice in PBS and incubated for 30 minutes.
- the percentage in phase G2 + M is calculated and the results are expressed according to a classification determined according to the percentage of cells accumulated in phase G2 + M after 21 hours compared to the control (control 20%)
- the compounds of the invention show an accumulation of more than 60% of the cells in G2-M phase after 21 hours for product concentrations ranging from 0.5 to
- the compounds of the invention show an induction of apoptosis at cytotoxic doses
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000554739A JP2002518398A (ja) | 1998-06-17 | 1999-06-09 | 新規アルテミシニン化合物、それらの製造方法、およびそれらを含有する医薬組成物 |
BR9911274-4A BR9911274A (pt) | 1998-06-17 | 1999-06-09 | Derivados da artemisinina, seus processos de preparação e as composições farmacêuticas que os contêm |
EP99923702A EP1086107A1 (fr) | 1998-06-17 | 1999-06-09 | Derives de l'artemisinine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
AU40474/99A AU748798B2 (en) | 1998-06-17 | 1999-06-09 | Artemisinin derivatives, method for the preparation thereof and pharmaceutical compositions containing the same |
HU0102599A HUP0102599A3 (en) | 1998-06-17 | 1999-06-09 | Artemisinin derivatives, method for the preparation thereof and pharmaceutical compositions containing the same |
CA002342990A CA2342990A1 (fr) | 1998-06-17 | 1999-06-09 | Derives de l'artemisinine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US09/719,767 US6307068B1 (en) | 1998-06-17 | 1999-06-09 | Artemisinin derivatives, method for the preparation thereof and pharmaceutical compositions containing the same |
NZ508388A NZ508388A (en) | 1998-06-17 | 1999-06-09 | Artemisinine derivatives, method for the preparation thereof and pharmaceutical compositions containing the same |
NO20006257A NO20006257L (no) | 1998-06-17 | 2000-12-08 | Artemisininderivater, fremgangsmåte ved fremstilling derav samt farmasöytiske sammensetninger inneholdende slike |
HK01107929A HK1036985A1 (en) | 1998-06-17 | 2001-11-12 | Artemisinin derivatives, method for the preparation thereof and pharmaceutical compositions containing the same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN98114788A CN1084333C (zh) | 1998-06-17 | 1998-06-17 | 新的青蒿素化合物,其制备方法以及含有它们的药物组合物 |
CN98114788.7 | 1998-06-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999065914A1 true WO1999065914A1 (fr) | 1999-12-23 |
Family
ID=5224325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1999/001359 WO1999065914A1 (fr) | 1998-06-17 | 1999-06-09 | Derives de l'artemisinine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Country Status (14)
Country | Link |
---|---|
US (1) | US6307068B1 (fr) |
EP (1) | EP1086107A1 (fr) |
JP (1) | JP2002518398A (fr) |
CN (2) | CN1084333C (fr) |
AU (1) | AU748798B2 (fr) |
BR (1) | BR9911274A (fr) |
CA (1) | CA2342990A1 (fr) |
HK (1) | HK1036985A1 (fr) |
HU (1) | HUP0102599A3 (fr) |
NO (1) | NO20006257L (fr) |
NZ (1) | NZ508388A (fr) |
PL (1) | PL344984A1 (fr) |
WO (1) | WO1999065914A1 (fr) |
ZA (1) | ZA200007070B (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005529938A (ja) * | 2002-06-06 | 2005-10-06 | ユニバーシティ オブ ワシントン | 癌の発症を予防または遅延するためのアルテミシニン様化合物を使用する方法 |
WO2009043538A1 (fr) * | 2007-10-04 | 2009-04-09 | Lachifarma S.R.L. Laboratorio Chimico Farmaceutico Salentino | Dérivés de l'artémisinine pour le traitement de mélanomes |
US7842720B2 (en) | 2004-06-21 | 2010-11-30 | Elsohly Laboratories, Incorporated | Anticancer and antiprotozoal dihydroartemisinene and dihydroartemisitene dimers with desirable chemical functionalities |
US8314142B2 (en) | 2006-04-11 | 2012-11-20 | Sanofi | Dimers of artemisinin derivatives, preparation thereof and therapeutic use thereof |
US8815942B2 (en) | 2010-10-20 | 2014-08-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Combination therapy and uses thereof for treatment and prevention of parasitic infection and disease |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003048167A1 (fr) * | 2001-12-06 | 2003-06-12 | Ufc Limited | Derives de trioxane |
GB0129215D0 (en) * | 2001-12-06 | 2002-01-23 | Ufc Ltd | Trioxane derivatives |
ATE427950T1 (de) * | 2001-12-06 | 2009-04-15 | Ufc Ltd | Trioxanderivate zur verwendung als antimalaria- oder antikrebs-verbindungen |
WO2003103592A2 (fr) * | 2002-06-06 | 2003-12-18 | University Of Washington | Conjugues covalents entre des endoperoxydes lies a l'artemisinine et des proteines porteuses de fer et procedes d'utilisation associes |
US6677463B1 (en) * | 2002-12-10 | 2004-01-13 | Council Of Scientific And Industrial Research | Single pot conversion of artemisinin to artesunic acid |
CN1327842C (zh) * | 2003-02-12 | 2007-07-25 | 沈恒 | 一种新型的抗肿瘤药物复方制备方法 |
CN1814601A (zh) | 2005-02-04 | 2006-08-09 | 中国科学院上海药物研究所 | 具有免疫抑制作用的青蒿素衍生物及药物组合物 |
GB0720967D0 (en) * | 2007-10-25 | 2007-12-05 | Protophama Ltd | Anti-material pharmaceutical composition |
GB2469791B (en) * | 2009-04-23 | 2011-12-14 | Londonpharma Ltd | Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of neoplastic disease |
WO2014023081A1 (fr) * | 2012-08-07 | 2014-02-13 | 中国科学院上海生命科学研究院 | Dérivés d'artémisinine, leur processus de préparation et leur utilisation |
US9663532B2 (en) | 2012-10-29 | 2017-05-30 | University Of Rochester | Artemisinin derivatives, methods for their preparation and their use as antimalarial agents |
CN117695222B (zh) * | 2024-02-06 | 2024-04-26 | 山东百奥生物医药有限公司 | 一种用于改善皮肤问题的青蒿素壬二酸酯-聚乙二醇二胺胶束及制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0428773A1 (fr) * | 1987-07-31 | 1991-05-29 | Dermatologic Research Corporation | Traitement des maladies de peau avec de l'artémisinine et des dérivés |
US5219880A (en) * | 1991-03-29 | 1993-06-15 | Dermatologic Research Corporation | Treatment of viral tumors and hemorrhoids with artemisinin and derivatives |
WO1996034602A1 (fr) * | 1995-05-03 | 1996-11-07 | University Of Washington | Procedes d'inhibition ou de destruction de cellules cancereuses |
WO1997001548A1 (fr) * | 1995-06-29 | 1997-01-16 | Hauser Chemical Research, Inc. | Composes dimeres d'artemisinine ayant une activite anticancereuse |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1049435A (zh) * | 1990-08-16 | 1991-02-20 | 中国对外贸易运输总公司 | 电传线路自动转换开关 |
CN1038416C (zh) * | 1992-12-04 | 1998-05-20 | 中国科学院上海药物研究所 | 新型青蒿素衍生物及其制备方法 |
CN1049435C (zh) * | 1994-11-09 | 2000-02-16 | 中国科学院上海药物研究所 | 含苯基和杂环基的青蒿素衍生物及其制备方法 |
-
1998
- 1998-06-17 CN CN98114788A patent/CN1084333C/zh not_active Expired - Fee Related
-
1999
- 1999-06-09 HU HU0102599A patent/HUP0102599A3/hu unknown
- 1999-06-09 JP JP2000554739A patent/JP2002518398A/ja active Pending
- 1999-06-09 CN CN99807416A patent/CN1111162C/zh not_active Expired - Fee Related
- 1999-06-09 PL PL99344984A patent/PL344984A1/xx not_active Application Discontinuation
- 1999-06-09 NZ NZ508388A patent/NZ508388A/en unknown
- 1999-06-09 BR BR9911274-4A patent/BR9911274A/pt not_active IP Right Cessation
- 1999-06-09 CA CA002342990A patent/CA2342990A1/fr not_active Abandoned
- 1999-06-09 AU AU40474/99A patent/AU748798B2/en not_active Ceased
- 1999-06-09 US US09/719,767 patent/US6307068B1/en not_active Expired - Fee Related
- 1999-06-09 EP EP99923702A patent/EP1086107A1/fr not_active Withdrawn
- 1999-06-09 WO PCT/FR1999/001359 patent/WO1999065914A1/fr not_active Application Discontinuation
-
2000
- 2000-11-30 ZA ZA200007070A patent/ZA200007070B/en unknown
- 2000-12-08 NO NO20006257A patent/NO20006257L/no not_active Application Discontinuation
-
2001
- 2001-11-12 HK HK01107929A patent/HK1036985A1/xx not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0428773A1 (fr) * | 1987-07-31 | 1991-05-29 | Dermatologic Research Corporation | Traitement des maladies de peau avec de l'artémisinine et des dérivés |
US5219880A (en) * | 1991-03-29 | 1993-06-15 | Dermatologic Research Corporation | Treatment of viral tumors and hemorrhoids with artemisinin and derivatives |
WO1996034602A1 (fr) * | 1995-05-03 | 1996-11-07 | University Of Washington | Procedes d'inhibition ou de destruction de cellules cancereuses |
WO1997001548A1 (fr) * | 1995-06-29 | 1997-01-16 | Hauser Chemical Research, Inc. | Composes dimeres d'artemisinine ayant une activite anticancereuse |
Non-Patent Citations (5)
Title |
---|
A.C. BEEKMAN ET AL., JOURNAL OF NATURAL PRODUCTS, vol. 60, no. 4, 1997, pages 325 - 330, XP002118823 * |
A.C. BEEKMAN ET AL., PHYTOTHERAPY RESEARCH, vol. 10, 1996, pages 140 - 144, XP002118822 * |
GUO-QIANG ZHENG, PLANTA MEDICA, vol. 60, no. 1, 1994, pages 54 - 57, XP002118820 * |
H.J. WOERDENBAG ET AL., JOURNAL OF NATURAL PRODUCTS, vol. 56, no. 6, 1993, pages 849 - 856, XP002118821 * |
MANKIL JUNG, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 7, no. 8, 1997, pages 1091 - 1094, XP004136191 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005529938A (ja) * | 2002-06-06 | 2005-10-06 | ユニバーシティ オブ ワシントン | 癌の発症を予防または遅延するためのアルテミシニン様化合物を使用する方法 |
US7842720B2 (en) | 2004-06-21 | 2010-11-30 | Elsohly Laboratories, Incorporated | Anticancer and antiprotozoal dihydroartemisinene and dihydroartemisitene dimers with desirable chemical functionalities |
US8314142B2 (en) | 2006-04-11 | 2012-11-20 | Sanofi | Dimers of artemisinin derivatives, preparation thereof and therapeutic use thereof |
WO2009043538A1 (fr) * | 2007-10-04 | 2009-04-09 | Lachifarma S.R.L. Laboratorio Chimico Farmaceutico Salentino | Dérivés de l'artémisinine pour le traitement de mélanomes |
US8507698B2 (en) | 2007-10-04 | 2013-08-13 | Lachifarma S.R.L. Laboratorio Chimico Farmaceutico Salentino | Artemisinin derivatives for the treatment of melanoma |
US8815942B2 (en) | 2010-10-20 | 2014-08-26 | The Royal Institution For The Advancement Of Learning/Mcgill University | Combination therapy and uses thereof for treatment and prevention of parasitic infection and disease |
US9278086B2 (en) | 2010-10-20 | 2016-03-08 | The Royal Institution For The Advancement Of Learning/Mcgill University | Combination therapy and uses thereof for treatment and prevention of parasitic infection and disease |
Also Published As
Publication number | Publication date |
---|---|
NO20006257D0 (no) | 2000-12-08 |
NO20006257L (no) | 2001-02-19 |
HUP0102599A2 (hu) | 2001-11-28 |
CN1111162C (zh) | 2003-06-11 |
US6307068B1 (en) | 2001-10-23 |
HUP0102599A3 (en) | 2003-03-28 |
HK1036985A1 (en) | 2002-01-25 |
EP1086107A1 (fr) | 2001-03-28 |
CN1239097A (zh) | 1999-12-22 |
PL344984A1 (en) | 2001-11-19 |
JP2002518398A (ja) | 2002-06-25 |
CA2342990A1 (fr) | 1999-12-23 |
AU4047499A (en) | 2000-01-05 |
CN1084333C (zh) | 2002-05-08 |
CN1305482A (zh) | 2001-07-25 |
AU748798B2 (en) | 2002-06-13 |
ZA200007070B (en) | 2001-10-18 |
NZ508388A (en) | 2003-07-25 |
BR9911274A (pt) | 2001-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999065914A1 (fr) | Derives de l'artemisinine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
CA2641138C (fr) | Dimeres de derives d'artemisinine, leur preparation et leur application en therapeutique | |
EP1103554A1 (fr) | Dérivés de dihydrofuro-(3,4-b) quinoléin-1-ones, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
EP1101770A1 (fr) | Nouveaux dérives de 12,13-(pyranosyl)-indolo(2,3-a)pyrrolo(3,4-c)carbazole et 12,13-(pyranosyl)-furo(3,4-c)indolo(2,3-a)carbazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
EP1095940B1 (fr) | Dérivés de 9-(3,5-diméthoxyphényl)-5,8,8a,9-tétrahydrofuro[3',4':6,7]naphto[2,3-d][1,3]dioxol-6(5aH)-one, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
EP1664055B9 (fr) | Derives de 9-amino-podophyllotoxine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
CA2315909C (fr) | Nouveaux derives de l'acronycine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
EP1292597B1 (fr) | Derives de podophyllotoxine carbamate et thiocarbamate, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
CA2448191A1 (fr) | Nouveaux derives tricycliques de dihydro-quinoleines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
EP1687312B1 (fr) | Molecules duales contenant un derive peroxydique, leur synthese et leurs applications therapeutiques | |
CA2174892A1 (fr) | Composes cyclohexaniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
CA2157156A1 (fr) | Nouveaux composes tetrahydropyraniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
US9771325B2 (en) | Tricyclic compounds and preparation thereof | |
EP0982308B1 (fr) | Dérivés de 8H-(2,3-b)-pyrrolizine-8-one, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
EP0082059A1 (fr) | Ethers d'oximes alpha-bêta insaturés, leur procédé de préparation et leur utilisation comme médicament | |
EP1556387B1 (fr) | Derives de benzo (e) (1,4) oxazino (3,2-g) isoindole substi tues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
CA2244508C (fr) | Nouveaux composes de bis pyrido¬4,3-b|carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
EP1399455A2 (fr) | Derives tricycliques de dihydroquinoleines,leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
CA2432807A1 (fr) | Derives de 1, 1-dioxo-2h-1, 2-benzothiazine-3-carboxamides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
WO2015121876A1 (fr) | Nouveaux composés tricycliques et leur procédé de préparation | |
FR2779144A1 (fr) | Nouveaux composes 8-amino-1,4-benzoxaziniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99807416.0 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN HU JP NO NZ PL US ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999923702 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 508388 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000/07070 Country of ref document: ZA Ref document number: 200007070 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09719767 Country of ref document: US Ref document number: 40474/99 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2342990 Country of ref document: CA Ref document number: 2342990 Country of ref document: CA Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1999923702 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 40474/99 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999923702 Country of ref document: EP |